Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California. Show more

Location: 7750 El Camino Real, Carlsbad, CA, 92009, United States | Website: https://www.palisadebio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

3.762M

52 Wk Range

$0.60 - $4.89

Previous Close

$0.78

Open

$0.77

Volume

120,021

Day Range

$0.75 - $0.79

Enterprise Value

-3.92M

Cash

7.242M

Avg Qtr Burn

-2.837M

Insider Ownership

0.46%

Institutional Own.

5.43%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.